Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition, contributing significantly to global morbidity and mortality. Traditional diagnostic tools are effective in diagnosing COPD. However, these tools demand specialized equipment and expertise. Advances in artificial intelligence (AI) provide a platform for enhancing COPD diagnosis by leveraging diverse data modalities. The existing reviews primarily focus on single modalities and lack information on interpretability and explainability. Thus, this review intends to synthesize the AI-powered frameworks for COPD identification, focusing on data modalities, methodological innovation, evaluation strategies, and reporting limitations and potential biases. By adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search was conducted across multiple repositories. From an initial pool of 1978 records, 22 studies were included in this review. The included studies demonstrated exceptional performance in specific settings. Most studies were retrospective and limited in diversity, lacking generalizability and external or prospective validation. This review presents a roadmap for advancing AI-assisted COPD detection. By highlighting the strengths and limitations of existing studies, it supports the development of future research. Future studies can utilize the findings to build models using prospective, multicenter, and multi-ethnic validations, ensuring generalizability and fairness.
Breast cancer remains the most prevalent cancer among women, where accurate and interpretable analysis of pathology images is vital for early diagnosis and personalized treatment planning. However, conventional single-network models fall short in balancing both performance and explainability—Convolutional Neural Networks (CNNs) lack the capacity to capture global contextual information, while Transformers are limited in modeling fine-grained local details. To overcome these challenges and contribute to the advancement of Explainable AI (XAI) in precision cancer diagnosis, this paper proposes MVT-OFML (Multi-View Transformer Online Fusion Mutual Learning), a novel and interpretable classification framework for breast cancer pathology images. MVT-OFML combines ResNet-50 for extracting detailed local features and a multi-view Transformer encoding module for capturing comprehensive global context across multiple perspectives. A key innovation is the Online Fusion Mutual Learning (OFML) mechanism, which enables bidirectional knowledge sharing between the CNN and Transformer branches by aligning both intermediate feature representations and prediction logits. This mutual learning framework enhances performance while also producing interpretable attention maps and feature-level visualizations that reveal the decision-making process of the model—promoting transparency, trust, and clinical usability. Extensive experiments on the BreakHis and BACH datasets demonstrate that MVT-OFML significantly outperforms the strongest baseline models, achieving accuracy improvements of 0.90% and 2.26%, and F 1 -score gains of 4.75% and 3.21%, respectively. By integrating complementary modeling paradigms with explainable learning strategies, MVT-OFML offers a promising AI solution for precise and interpretable breast cancer diagnosis and prognosis, supporting informed decision-making in clinical settings.
breast cancerhistopathological image classificationexplainable AICNN-Transformer hybrid
Hematological biomarkers have emerged as powerful tools in diagnosing Acute Heart Failure (AHF). This study introduces a novel diagnostic framework that integrates Explainable Artificial Intelligence (XAI) with Morris Sensitivity Analysis (MSA) to enhance both the interpretability and performance of machine learning models in AHF detection. A dataset consisting of 425 AHF patients and 430 controls was analyzed using eight machine learning models, including XGBoost, Histogram-based Gradient Boosting (histGB), Explainable Boosting Machine (EBM), and Random Forest. Model performance was evaluated through metrics such as AUC, accuracy, precision, recall, and Brier score. Hyperparameters were optimized via Bayesian optimization. Feature importance was assessed using MSA to identify variables with the highest predictive influence. The histGB model achieved the highest performance with an AUC of 87.93%. Both MSA and EBM consistently identified PDW, RDW-CV, NEU, NEU/LY ratio, age, and WBC as top predictive features across multiple models. These hematological markers demonstrated strong potential for early diagnosis and risk stratification in AHF patients. This study presents a clinically relevant, interpretable, and cost-effective diagnostic strategy that combines XAI with MSA for AHF prediction. The framework enhances clinical trust and provides a pathway toward personalized treatment by identifying accessible hematological biomarkers. The integration of explainability into AI models improves their transparency and applicability in real-world clinical settings.